Form 4: Bicycle Therapeutics CFO Reports Equity Transactions

Bicycle Therapeutics CFO Alethia Young reported the acquisition of restricted stock units and stock options, alongside 'sell to cover' transactions for tax obligations.

Summary

• Alethia Young, Chief Financial Officer of Bicycle Therapeutics PLC (BCYC), reported several transactions involving the company's ordinary shares and employee stock options.
• On January 2, 2026, Young was awarded 50,000 Restricted Share Units (RSUs) at a price of $0, representing a contingent right to receive one ordinary share per RSU.
• One-fourth (1/4) of these RSUs are scheduled to vest on January 2, 2027, with the remaining vesting in 12 equal quarterly installments thereafter.
• Also on January 2, 2026, Young was granted 100,000 employee stock options with an exercise price of $7.08, expiring on January 2, 2036.
• One-fourth (1/4) of these options will vest on January 2, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.
• Young disposed of 3,289 ordinary shares on January 2, 2026, at a weighted average price of $6.8, ranging from $6.62 to $7.11.
• On January 5, 2026, Young disposed of an additional 2,456 ordinary shares at a weighted average price of $6.45, ranging from $6.30 to $6.70.
• A further 1,878 ordinary shares were disposed of on January 5, 2026, at a weighted average price of $6.54, ranging from $6.5237 to $6.5412.
• The share dispositions were primarily 'sell to cover' transactions mandated by the award agreements to satisfy statutory tax withholding obligations, not discretionary sales.
• One of the dispositions on January 5, 2026, was executed pursuant to a Rule 10b5-1 trading plan adopted on April 3, 2025.
• Following these transactions, Young's direct beneficial ownership of ordinary shares stands at 87,081, in addition to 100,000 derivative securities (employee stock options).

Sentiment

Score: 5

Explanation: The filing reports routine insider equity transactions related to compensation and tax obligations. It does not contain information that would significantly alter the company's fundamental outlook or market sentiment, hence a neutral score.

Positives

• The Chief Financial Officer received a significant award of 50,000 Restricted Share Units (RSUs) and 100,000 employee stock options, indicating continued alignment of management incentives with shareholder interests.
• The dispositions of shares were non-discretionary 'sell to cover' transactions for tax withholding, rather than voluntary sales, which suggests no negative sentiment from the insider regarding the company's prospects.

Negatives

• The 'sell to cover' transactions resulted in a reduction of the Chief Financial Officer's direct beneficial ownership of ordinary shares by a total of 7,623 shares.

Future Outlook

The vesting schedules for the Restricted Share Units and employee stock options extend into future years, with initial vesting on January 2, 2027, and subsequent installments over several years, indicating a long-term incentive structure for the Chief Financial Officer.

Management Comments

• The sales of shares were mandated by the Reporting Person's award agreement to satisfy minimum statutory tax withholding obligations through a 'sell to cover' transaction, and do not represent a discretionary sale.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, common across publicly traded companies, particularly in the biotechnology sector where equity compensation is a standard component of executive remuneration. It provides transparency into executive holdings and compensation mechanisms.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding the equity holdings and compensation structure of a key executive, which can influence investor confidence.
• Employees: Highlights the use of equity-based compensation (RSUs and stock options) as part of executive remuneration, which is a common practice across the industry.

Next Steps

• The first tranche of 1/4 of the RSU award and employee stock options will vest on January 2, 2027.
• Remaining RSUs will vest in 12 equal quarterly installments after January 2, 2027.
• Remaining employee stock options will vest in 36 equal monthly installments after January 2, 2027.

Key Dates

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Trading, Restricted Share Units, Stock Options, CFO, Equity Compensation, Sell to Cover